159 related articles for article (PubMed ID: 36199799)
1. MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells.
Duan X; Xie Y; Yu J; Hu X; Liu Z; Li N; Qin J; Lan L; Yuan M; Pan Z; Wang Y
J Oncol; 2022; 2022():3659714. PubMed ID: 36199799
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
3. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Shao B; Li CW; Lim SO; Sun L; Lai YJ; Hou J; Liu C; Chang CW; Qiu Y; Hsu JM; Chan LC; Zha Z; Li H; Hung MC
Am J Cancer Res; 2018; 8(9):1837-1846. PubMed ID: 30323975
[TBL] [Abstract][Full Text] [Related]
4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
5. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
Cheung A; Chenoweth AM; Quist J; Sow HS; Malaktou C; Ferro R; Hoffmann RM; Osborn G; Sachouli E; French E; Marlow R; Lacy KE; Papa S; Grigoriadis A; Karagiannis SN
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884422
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract][Full Text] [Related]
9. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
[TBL] [Abstract][Full Text] [Related]
10. Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer.
Desterke C; Xiang Y; Elhage R; Duruel C; Chang Y; Hamaï A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201582
[TBL] [Abstract][Full Text] [Related]
11. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
12. Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling.
Zhang Q; Yang Z; Hao X; Dandreo LJ; He L; Zhang Y; Wang F; Wu X; Xu L
Cell Biosci; 2023 Oct; 13(1):192. PubMed ID: 37848943
[TBL] [Abstract][Full Text] [Related]
13. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
Yoon HK; Kim TH; Park S; Jung H; Quan X; Park SJ; Han J; Lee A
Pathol Res Pract; 2018 Oct; 214(10):1626-1631. PubMed ID: 30139555
[TBL] [Abstract][Full Text] [Related]
14. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
16. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
17. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
18. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
19. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):87. PubMed ID: 29615063
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Guo L; Li W; Zhu X; Ling Y; Qiu T; Dong L; Fang Y; Yang H; Ying J
Springerplus; 2016; 5(1):805. PubMed ID: 27390646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
